Literature DB >> 6937475

Platelet Fc receptor. Increased expression in myeloproliferative disease.

A Moore, R L Nachman.   

Abstract

The platelet Fc receptor, a membrane receptor for immune complexes or aggregated immunoglobulin (Ig)G, was compared in normal and myeloproliferative platelets. Washed platelets from 11 normal donors and 27 patients were incubated with fluorescein-conjugated ovalbumin-anti-ovalbumin complexes and examined by phase and fluorescence microscopy. Only 3.2+/-1% of the normal platelets stained, whereas 76+/-16% of the myeloproliferative platelets stained with the immune complex. The fluorescent staining was mediated by a platelet Fc receptor, as shown by the absence of platelet staining with immune complex containing antibody preincubated with Staphylococcal protein A to block the Fc region. In addition, no staining occurred with antigen or antibody alone or after preincubation of platelets with aggregated IgG. Platelets from normal or myeloproliferative donors did not stain with the immune complexes when the incubation was performed in plasma. The increased expression of Fc receptors on myeloproliferative platelets was corroborated by studies of [(14)C]serotonin release by immune complexes or aggregated IgG in 8 patients and 17 normal donors. Serotonin uptake was similar in both groups. Myeloproliferative platelets released significantly more serotonin than normal platelets at each concentration of immune complex or aggregated IgG; in addition, myeloproliferative platelets released serotonin in response to much smaller concentrations of immune complex or aggregated IgG. [(14)C]Serotonin release by myeloproliferative platelets was not increased above that of normal platelets when thrombin was used as the stimulus. The results were independent of patient age, sex, therapy, hematocrit, or platelet size. Interaction of circulating immune complexes with platelets bearing increased Fc receptors may contribute to the abnormal hemostasis associated with the myeloproliferative syndromes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6937475      PMCID: PMC370665          DOI: 10.1172/jci110118

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Mediterranean macrothrombocytopenia.

Authors:  W E Behrens
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Lactic dehydrogenase activity in blood.

Authors:  F WROBLEWSKI; J S LADUE
Journal:  Proc Soc Exp Biol Med       Date:  1955-10

3.  The treatment of polycythemia vera.

Authors:  L R Wasserman
Journal:  Semin Hematol       Date:  1976-01       Impact factor: 3.851

4.  Diagnosis and classification of the polycythemias.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

5.  Electronic platelet counts with the Coulter counter. Reassessment of a correction factor.

Authors:  E L Gottfried; J Wehman; B Wall
Journal:  Am J Clin Pathol       Date:  1976-09       Impact factor: 2.493

6.  Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: ultrastructure and peroxidase reaction.

Authors:  J E Maldonado; T Pintado; R V Pierre
Journal:  Blood       Date:  1974-06       Impact factor: 22.113

7.  Quantitation of platelet aggregation in myeloproliferative disorders.

Authors:  J A Neemeh; E J Bowie; J H Thompson; P Didisheim; C A Owen
Journal:  Am J Clin Pathol       Date:  1972-03       Impact factor: 2.493

Review 8.  The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.

Authors:  H P Ward; M H Block
Journal:  Medicine (Baltimore)       Date:  1971-09       Impact factor: 1.889

9.  Polycythemia vera: stem-cell and probable clonal origin of the disease.

Authors:  J W Adamson; P J Fialkow; S Murphy; J F Prchal; L Steinmann
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

10.  Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses.

Authors:  P M Henson; H L Spiegelberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  7 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Authors:  R B Stricker; P T Reyes; L Corash; M A Shuman
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

Review 3.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

Review 4.  Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.

Authors:  Beste Ozben; Ahmet Ekmekci; Zehra Bugra; Sabahattin Umman; Mehmet Meric
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

5.  Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia.

Authors:  N B Westwood; E R Copson; L A Page; A R Mire-Sluis; K A Brown; T C Pearson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

6.  Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.

Authors:  H Ludwig; W Linkesch; H Gisslinger; E Fritz; H Sinzinger; T Radaszkiewicz; A Chott; R Flener; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Identification of a third component of complement-binding glycoprotein of human platelets.

Authors:  G H Yu; V M Holers; T Seya; L Ballard; J P Atkinson
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.